Peter Mac Cancer Centre
@PeterMacCC
Followers
14K
Following
1K
Media
1K
Statuses
4K
Peter Mac is an integrated cancer research, treatment and education centre. A place where normal days are extraordinary – as are the people we care for.
Australia
Joined February 2013
Congrats to Prof Karin (Kas) Thursky and team on the launch of the new Centre for Health Services Research in Cancer!. It will transform cancer care delivery by embedding patient voices, data and system-level innovation into everyday practice. 🔗
0
3
22
Congrats to Jennifer Doubell OAM – who was last night named a Distinguished Fellow of Peter Mac, our highest honour, for her extraordinary impact on cancer research and care. Read more:
1
1
8
In the news today: Peter Mac scientists have developed “Precision Guided Munition” CAR T-cells – smart immune cells that target solid tumours directly. In lab models, they wiped out breast, colon & ovarian tumours with cure rates near 100%!. More:
0
12
31
A clinical trial, co-led by Peter Mac’s Prof Danny Rischin, has shown promising results for preventing hearing impairment as a side effect of cisplatin - a widely used cancer drug. More:
0
0
2
Peter Mac’s Dr @MariaFtanou joined @RadioNational to explore why we often struggle to talk about cancer — and why it’s so important that we do. She shares insights from her work as a clinical psychologist and researcher. 🎧 Listen here:
0
2
12
Proud to welcome @MaryAnneThomas for the launch of the Parkville Precinct Strategic Cancer Service Plan 2025–2035. Thank you to our partners @TheRMH & @TheWomens for your collaboration as we work to transform cancer care over the next decade. More:
0
0
6
Peter Mac nurses are leading the way in cancer care. From genomics to survivorship, their work shone at the @CNSA_ORG & ICCN Congress – with powerful presentations, awards & global recognition. 👏. Read more: #CancerNursing #CNSA2025
0
0
7
Peter Mac’s Prof @MAF_Dawson has won the 2025 @ASH_hematology William Dameshek Prize – the first Australian to receive this top honour for his world-leading work in epigenetics. More:
0
1
20
Peter Mac trial suggests a way to dramatically improve outcomes in patients with high-risk forms of large B-cell lymphoma. 💊 Standard chemo + new drug glofitamab.✅ 98% complete response.🔒 86% progression-free at ~2 years.📈 92% overall survival. MORE:
0
2
6
Proud to host the 5th NET Preceptorship at Peter Mac — bringing together experts from across 🇦🇺 to share knowledge on diagnosing & treating rare neuroendocrine tumours. An electric first day today with so much more to come tomorrow! . 🔗
0
0
8
A "game-changing treatment for hidden cancer" that's tipped as practice changing featured in @theage with Peter Mac's Prof Danny Rischin explaining how an immunotherapy drug is having a big impact on patients with cutaneous squamous cell carcinoma. More:
0
1
9
Prof @_ShankarSiva has received a $1.5M MRFF grant to lead PRIME-Lung — a trial testing if radiotherapy to the primary tumour can boost outcomes in advanced lung cancer (NSCLC). 🔗 Read more:
3
10
54
A record number of Peter Mac researchers presented at #ASCO25 — with global-impact trials, theranostics leadership, ctDNA breakthroughs & more. 🌍. “Our presence is getting bigger and more impactful each year.” – Prof Jayesh Desai. Read more:
4
8
38
RT @PeterMacRadOnc: Ground-breaking, practice-changing research from Prof Danny Rischin & Prof Sandro Porceddu @PeterMacCC and brilliant te….
0
6
0
RT @TiansterZhang: First 161-terbium-PSMA trial in mCRPC - @DrMHofman @PeterMacCC presents good 40% PSA 50 decline, mPFS 9mo, and plans for….
0
13
0
An experimental therapy involving radioactive Terbium, and designed to seek out and kill prostate cancer cells wherever they are in the body, has shown very positive initial results in a first-in-human clinical trial at Peter Mac. Read more:
#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy @ASCO #ASCO25. First prospective trial of Terbium-161 in any tumour type.🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq).🟣 Very few side effects: 1 grade 3
1
5
15
RT @ANZUPtrials: Our @ANZUPtrials #PCRMIB poster featured at #ASCO25. Well done to @WeickhardtOnc and the entire team for this important #b….
0
5
0
RT @drshieldsmd: Expert discussant #RadOnc Professor Shankar Siva @_ShankarSiva @PeterMacCC bringing Professor #Sparkles to dissect lung or….
0
8
0
A new Peter Mac-led trial shows cemiplimab could stop high-risk #skincancer (cSCC) from returning — and reduce disfiguring surgery. 📉 Recurrence: 30% ➡️ 9%.📈 2-year survival: 64% ➡️ 87%.Presented at #ASCO25 | Published in NEJM 📚. 🔗
0
0
4
RT @CancerAustralia: Join Cancer Australia, @PeterMacCC and @VCCCAlliance at the ACCN Innovations Showcase on Thursday, 3 July at Peter Mac….
0
3
0